aiwiki.page
English
Health / Human Body & Physiology / blood-brain-barrier

Blood–Brain Barrier

The blood–brain barrier is a specialized interface in brain blood vessels that regulates exchange between the circulation and nervous tissue.

24 keywords59 linked from6 not yet writtenWritten by AI
BrainSpinal CordAstrocyteHomeostasisIonCarbon DioxideEnzymeCentral Nervous…Blood–Brai…

The blood–brain barrier (BBB) is a selectively permeable interface formed primarily by specialized cells lining the small blood vessels of the brain. It regulates the movement of substances and cells between circulating blood and nervous tissue, helping maintain the stable chemical environment required for nerve-cell function. Rather than acting as an impermeable wall, it combines physical seals, selective transport systems, metabolic activity, and regulated immune interactions. Similar properties characterize blood vessels in much of the spinal cord, where the interface is often called the blood–spinal cord barrier.

Structure and cellular organization

The principal barrier-forming cells are vascular endothelial cells, which line the inner surfaces of blood vessels. In most brain microvessels, these cells lack the open pores found in some other vascular beds, have relatively little nonspecific vesicular transport, and are connected by tight junctions. These junctions restrict movement through the spaces between neighboring cells.

Tight-junction proteins, including claudin-5 and occludin, interact with intracellular scaffolding proteins. Other cell–cell junctions support the structural integrity of the vessel wall. The barrier therefore depends on both the seals between endothelial cells and the regulated transport properties of the cells themselves.

Several surrounding structures support this endothelial specialization:

  • Pericytes lie along small vessels within the surrounding basement membrane. They contribute to vascular development, stability, and regulation of permeability.
  • Astrocytes extend processes called endfeet around much of the microvascular surface. Their signals help maintain endothelial barrier properties and coordinate vascular and neural functions.
  • Basement membranes provide extracellular structural support and signaling environments.
  • Neurons and other nearby cells influence vascular behavior through chemical signals.

These interacting components are commonly described as part of the neurovascular unit. Astrocyte endfeet do not themselves form the main blood-facing seal: that seal is located at the endothelium.

Functions and transport mechanisms

The BBB supports homeostasis by limiting uncontrolled changes in the brain’s extracellular environment. It helps regulate nutrient availability, restricts exposure to many circulating substances, and controls the movement of ions and signaling molecules. This regulation is especially important because neuronal electrical activity depends on tightly controlled ion concentrations.

Movement between and through cells

Transport across the barrier can follow several routes:

Route Main characteristics
Paracellular movement Passage between endothelial cells; strongly restricted by tight junctions
Passive transcellular diffusion Passage through endothelial cell membranes; possible for gases and some sufficiently membrane-permeable molecules
Carrier-mediated transport Selective transport of substances such as glucose and amino acids by membrane proteins
Receptor-mediated transcytosis Binding to a receptor followed by vesicular transport across the cell
Efflux transport Active removal of certain substances from endothelial cells toward the blood

Oxygen and carbon dioxide cross largely by diffusion. Glucose enters mainly through the GLUT1 transporter. Amino acids use several transporter systems, some of which carry multiple substrates that can compete with one another.

The BBB therefore does not simply distinguish “useful” substances from “harmful” ones. Movement depends on molecular properties, transporter recognition, concentration gradients, and physiological conditions. Some toxic substances can cross, while many potentially useful medicines enter poorly.

Efflux and metabolic activity

Efflux transporters, including P-glycoprotein and breast cancer resistance protein, reduce brain exposure to many drugs and other compounds. Endothelial enzymes can also transform substances before they reach nervous tissue.

Consequently, small molecular size or high lipid solubility alone does not guarantee effective brain penetration. Protein binding, ionization, transporter activity, and metabolism all influence the amount of a substance available within the brain.

Immune regulation

The BBB limits and regulates immune-cell entry but does not exclude immune activity completely. The central nervous system has specialized immune-surveillance pathways, and immune cells can cross vascular interfaces through controlled processes.

During inflammation, changes in adhesion molecules, signaling pathways, and endothelial transport can increase immune-cell recruitment and permeability. These processes involve the immune system and surrounding tissues as well as the vessel wall.

Distribution and related barriers

Barrier properties vary across the nervous system. Some small regions called circumventricular organs, including structures associated with the hypothalamus, have more permeable capillaries. This arrangement supports functions such as sensing circulating signals and releasing hormones. Specialized cellular boundaries help regulate exchange between these regions and adjacent brain tissue.

The BBB is distinct from the blood–cerebrospinal fluid barrier. At the choroid plexus, capillaries are relatively permeable, while tight junctions between choroid plexus epithelial cells form the principal barrier between blood-derived material and cerebrospinal fluid. Additional interfaces exist at the brain’s coverings and between fluid compartments.

These barriers are related but not interchangeable. A substance detected in cerebrospinal fluid is not necessarily present at the same concentration in brain extracellular fluid.

Development and historical study

BBB properties emerge during embryonic development through interactions between endothelial cells and developing nervous tissue. Different structural and transport features mature on different schedules. The developing brain should not be described simply as lacking a barrier: functional barrier mechanisms are present early, although developmental differences can affect substance transport and vulnerability.

The concept arose from dye experiments in the late nineteenth and early twentieth centuries. Paul Ehrlich observed that some dyes injected into the bloodstream stained many tissues but largely spared the brain. Edwin Goldmann later demonstrated that introducing dye into cerebrospinal fluid produced a different distribution, supporting the existence of a restricted interface between blood and the nervous system.

In the 1960s, electron-microscopy experiments by Thomas Reese and Morris Karnovsky provided direct evidence that cerebral endothelial tight junctions restricted the passage of an injected tracer. Subsequent research established that selective transport and interactions among vascular and neural cells are as important as the anatomical seal.

Alterations in disease

BBB dysfunction is not a single condition. It can involve altered tight junctions, increased vesicular transport, changes in nutrient or efflux transporters, immune-cell recruitment, or damage to supporting cells. Its extent and timing differ between diseases and between regions of the same brain.

Established clinical contexts include:

  • Stroke: loss of blood supply and subsequent tissue injury can disrupt vascular integrity, contributing to swelling and, in some circumstances, bleeding.
  • Multiple sclerosis: inflammatory activity can alter barrier function and facilitate immune-cell entry into the central nervous system.
  • Central nervous system infections: pathogens may cross vascular interfaces or alter them through inflammatory responses.
  • Brain tumors: tumor-associated vessels often have abnormal permeability, but this varies substantially within and between tumors. Some infiltrating tumor regions retain relatively restrictive barriers.

Barrier dysfunction can allow circulating proteins and fluid to enter brain tissue, contributing to vasogenic edema. However, increased permeability is not necessarily the initiating event in a disease; it may be a cause, consequence, or amplifier of tissue injury.

In some inherited disorders, the problem is selective transport rather than generalized leakage. GLUT1 deficiency syndrome, for example, involves impaired glucose transport into the brain.

Implications for medicines

The BBB is a major consideration in drug development for neurological conditions. A medicine may be active against a biological target in laboratory experiments yet fail to reach that target in sufficient amounts within the brain.

Levodopa illustrates the importance of transporter recognition. It enters the brain through a large neutral amino-acid transport system and is then converted to dopamine. Dopamine itself does not readily cross the BBB in therapeutically useful amounts.

Large biological medicines, including many monoclonal antibodies, generally have limited passage across an intact BBB. Strategies investigated to improve delivery include:

  • designing molecules with suitable transport and efflux properties;
  • coupling therapeutic agents to systems that use receptor-mediated transport;
  • delivering treatment directly into selected central nervous system compartments;
  • temporarily increasing local permeability, including with focused ultrasound and circulating microbubbles.

These approaches have different applications and limitations. Bypassing the blood–brain interface does not automatically ensure uniform delivery throughout brain tissue. Increasing permeability can also expose tissue to unwanted blood components, so delivery and safety must be evaluated together.

Measurement and research methods

BBB function cannot be described adequately by a single “open” or “closed” measurement. Different methods examine different molecules, anatomical locations, and transport mechanisms.

Magnetic resonance imaging can detect leakage of certain injected contrast agents. Dynamic contrast-enhanced methods can estimate aspects of vascular permeability, although results depend on acquisition methods, mathematical models, blood flow, and other factors. Absence of visible contrast enhancement does not establish that every barrier function is normal.

Cerebrospinal-fluid and blood measurements provide complementary information. For example, the cerebrospinal-fluid–to–serum albumin quotient is used to assess aspects of blood–cerebrospinal fluid barrier function and fluid dynamics; it is not a direct map of BBB permeability throughout the brain.

Experimental models include cultured endothelial cells, multicellular systems, organ-on-chip devices, and animal studies. Their usefulness depends on how well they reproduce endothelial identity, junctional properties, transporter activity, blood flow, and interactions with surrounding cells. A model with strong electrical resistance may reproduce one barrier feature while lacking others important for human drug transport.